0000000000825811

AUTHOR

Giuseppe Lassandro

showing 9 related works from this author

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management

2015

MaleAutoantibodies; Blood Coagulation Factor Inhibitors; Female; Humans; Male; Hemophilia A; Immunology and Allergy; HematologyBlood Coagulation Factor InhibitorsHumansImmunology and AllergyBlood Coagulation Factor InhibitorFemaleHematologyRecommendationHemophilia AAutoantibodieHumanAutoantibodies
researchProduct

Pain assessment and management in Italian Haemophilia Centres

2021

BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH. MATERIALS AND METHODS: Between September and October 2017, a questionnaire was distributed to 35 Italian haemophilia treatment centres (60 physicians). RESULTS: Fifty-three haemophilia specialists completed the survey. We found that there was good agreement (98.1%) on the need to investigate pain at each clinical visit, but there was h…

Factor IXItalyHumansPain Managementpain heamophiliaHemophilia Ablood coagulation disorders haemophilia pain perception pain management surveysHaemostasis and ThrombosisPain Measurement
researchProduct

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

2019

Abstract The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhib…

medicine.medical_specialtyFactor concentrate610 Medicine & healthReview Article030204 cardiovascular system & hematologyHemophilia ADrug SubstitutionHemophilia BFactor IX03 medical and health sciencesDrug substitution0302 clinical medicinePharmacokineticsmedicineDosingIntensive care medicineFactor IXClotting factorOriginal Articles: Haemostasisfactor IXFactor VIIIlcsh:RC633-647.5business.industryDosing regimenlcsh:Diseases of the blood and blood-forming organsHematology3. Good healthOnline‐only Articlesfactor VIII3121 General medicine internal medicine and other clinical medicinedrug substitution10032 Clinic for Oncology and Hematologydrug substitution; factor IX; factor VIII; hemophilia A; hemophilia Bhemophilia Bhemophilia Abusiness030215 immunologymedicine.drug
researchProduct

Idiopathic neutropenia of infancy: Data from the Italian Neutropenia Registry.

2019

Autoimmune neutropenia of infancy (AIN) is characterized by low risk of severe infection, tendency to spontaneously resolve and typically onset at ≤4-5 years of age; it is due to auto-antibodies whose detection is often difficult. In case of negativity of 4 antineutrophils autoantibody tests, after having excluded ethnic, postinfection, drug induced, or congenital neutropenia, according to the Italian guidelines the patients will be defined as affected by "idiopathic neutropenia" (IN). We describe the characteristics of 85 IN patients enrolled in the Italian neutropenia registry: they were compared with 336 children affected by AIN. The 2 groups were clinically very similar and the main dif…

Malemedicine.medical_specialtyNeutropeniaAutoimmunityNeutropeniaDiagnosis Differential03 medical and health sciences0302 clinical medicineSex FactorsMonocytosisRisk FactorsInternal medicineDiagnosismedicineCongenital Bone Marrow Failure SyndromesHumansRegistriesCongenital NeutropeniaHematologyLeukopeniabusiness.industryAge Factors; Autoimmunity; Congenital Bone Marrow Failure Syndromes; Diagnosis Differential; Female; Humans; Infant; Italy; Leukopenia; Male; Neutropenia; Registries; Risk Factors; Sex FactorsAutoantibodyAge FactorsInfantHematologyLeukopeniamedicine.diseaseSettore MED/38Italy030220 oncology & carcinogenesisAutoimmune neutropeniaDifferentialFemalemedicine.symptomDifferential diagnosisbusiness030215 immunologyAmerican journal of hematology
researchProduct

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

2019

The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia A (HA). The Italian health care system has authorized the use of a wide range of rFVIII concentrates of the first, second, and third generation, as well as new innovative rFVIII preparates with an extended half-life (EHL) (Kogenate FS®-Bayer, belonging to the second generation and replaced since 2017 by a product consisting of the same modified molecule; because it is only available until the end of the current year, it w…

Review030204 cardiovascular system & hematologyPharmacologyHemophilia ARecombinant factor viii03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesinhibitorsMoroctocog alfaEHL-rFVIIIMedicineHemophilia A recombinant Factor VIII products pharmacokinetics inhibitors EHL-rFVIIIlcsh:R5-920biologybusiness.industryvirus diseasesrecombinant Factor VIII productsGeneral MedicineTuroctocog alfaThird generationPharmacodynamicsbiology.proteinMedicineSimoctocog alfabusinesslcsh:Medicine (General)pharmacokinetics030215 immunologyClearanceFrontiers in Medicine
researchProduct

Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC

2020

Background: Careful assessment of bleeding history is the first step in the evaluation of patients with mild/moderate bleeding disorders, and the use of a bleeding assessment tool (BAT) is strongly encouraged. Although a few studies have assessed the utility of the ISTH-BAT in patients with inherited platelet function disorders (IPFD) none of them was sufficiently large to draw conclusions and/or included appropriate control groups. Objectives: The aim of the present study was to test the utility of the ISTH-BAT in a large cohort of patients with a well-defined diagnosis of inherited platelets disorder in comparison with two parallel cohorts, one of patients with type-1 von Willebrand disea…

bleeding assessment toolSYMPTOMSMedicina Clínica030204 cardiovascular system & hematologyBLEEDING DISORDERS0302 clinical medicinePlateletINHERITED PLATELET DISORDERSUTILITYRISKbleeding disordersCommunicationbleeding assessment tool; bleeding diathesis; bleeding disorders; inherited platelet disorders; plateletsbleeding diathesisHematologyPLATELETSvon Willebrand DiseasesplateletsBLEEDING DIATHESISLife Sciences & BiomedicineVON-WILLEBRAND-DISEASEmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDPlatelet Function TestsPlatelet disorderQUESTIONNAIREinherited platelet disorderHemorrhageDIAGNOSIS03 medical and health sciencesInternal medicineSCOREmedicineVon Willebrand diseaseHumansHematologíaIn patientbleeding disorderBLEEDING ASSESSMENT TOOLScience & Technologybleeding diathesibusiness.industrySettore MED/09 - MEDICINA INTERNAMILDmedicine.diseaseLarge cohortBleeding diathesisPeripheral Vascular Diseaseinherited platelet disordersCardiovascular System & CardiologyBlood Platelet Disordersbusiness
researchProduct

ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers

2021

AbstractConsidering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.…

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHemophilia ASevere hemophilia AABO Blood-Group SystemVon Willebrand factorhemic and lymphatic diseasesInternal medicineABO blood group systemABO blood group; hemophilia; inhibitors; risk factorshemophiliainhibitorsHumansMedicinerisk factorsIn patientBlood typebiologybusiness.industryABO blood groupHematologyinhibitorItalyHemostasisbiology.proteinFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres

2022

Although synovitis is recognized as a marker of joint disease activity, its periodic assessment is not included in routine clinical surveillance of patients with haemophilia (PwH). In order to evaluate the current knowledge and to identify controversial issues, a preliminary literature search by the Musculoskeletal Committee of the Italian Association of Haemophilia Centres (AICE) has been conducted. Statements have been established and sent to the Italian AICE members to collect their level of agreement or disagreement by a Delphi process. Thirty-seven consensus recommendations have been drafted. We found a general agreement on the indication to consider the presence of synovitis as a mark…

haemophilia; haemophilic arthropathy; synovitis; Chronic Disease; Consensus; Hemophilia A; Humans; Italy; Synovitishaemophilia haemophilic arthropathy synovitisConsensusSynovitisItalyChronic Diseasehaemophilic arthropathyhaemophiliaHumansHematologyHemophilia ABritish Journal of Haematology
researchProduct

Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project.

2021

: Regular physical activity can increase joint stability and function, reduce the risk of injury, and improve quality of life of people with haemophilia (PwH). However, a recent review of the literature shows that appropriate physical activity and sport are not always promoted enough in the overall management of PwH. A group of Italian experts in haemophilia care undertook a consensus procedure to provide practical guidance on when and how to recommend physical exercise programmes to PwH in clinical practice. Three main topics were identified -haemophilia and its impact on movement, physical activity recommendations for PwH, and choice and management of sports activity in PwH- and ten state…

ConsensusrecommendationsQuality of Lifehaemophiliaphysical activityHumansProspective StudiessportHemophilia AExerciseHaemostasis and ThrombosisBlood transfusion = Trasfusione del sangue
researchProduct